CLA May Benefit Mild Asthmatics
MacRedmond R et al., “Conjugated linoleic acid improves airway hyper-reactivity in overweight mild asthmatics,” Journal of Clinical & Experimental Allergy, vol. 40 (July 2010): 1071-78.
In what Cognis Nutrition & Health (La Grange, IL) says is the first study of its kind, researchers studied the effects of Cognis’s Tonalin conjugated linoleic acid (CLA) ingredient, touted for weight and body-fat management, on mild asthmatics.
The 12-week, randomized, double-blind, placebo-controlled study, funded in part by Cognis, involved 28 adults (ages 19 to 40) with mild asthma. Subjects were randomized to received 4.5 g/day of CLA or placebo, in addition to their usual asthma treatment.
The researchers found that Tonalin improved airway hyperreactivity in overweight, mildly asthmatic adults. Researchers also determined a significant improvement in the subjects’ tolerance for strenuous exercise. Moreover, Tonalin subjects also reduced their body weight and Body Mass Index by an average of 4.4 lb and 0.5 kg/m2, respectively, which the researchers say was associated with a metabolically favorable change in adipokine concentrations.
“We encourage further studies to elucidate the role of CLA in a broader asthma population,” the researchers stated.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
The 2023 Supplement Consumer: Immune Health and Beyond
April 19th 2024Did you know two-out-of-three U.S. supplement consumers say their immune health has become more important to them, yet only 38% would describe their immune health as “very healthy?” There’s an opportunity to meet consumers in their growing desire to live healthier lifestyles and help them redefine resilience. IMMUSETM is the universal postbiotic for year-round immune support. Unlock exclusive consumer insights and discover the formulation opportunities with IMMUSETM with this consumer research.
